Wanbury starts commercial production of high-potent anaesthetic API at Tanuku facility

28 Jan 2026 Evaluate

Wanbury has commenced commercial production for a high-potent anaesthetic API at its state-of-the-art facility in Tanuku, Andhra Pradesh. This positions the company to capture robust revenue growth for Q4FY26 and FY27. The new API is expected to generate incremental revenues of around Rs 18 crore in Q4 FY 2025-26.

Complementing this development, the company’s upcoming multi-purpose intermediate production block at Tanuku is on track for commercial readiness by the end of March 2026. This versatile facility will enable the production of four additional high-value APIs: Antidiabetic, Anticoagulant (Blood thinner), Cough suppressant (Anti Tussive), Antidepressant. Together, these four molecules are projected to deliver over Rs 100 crore in revenues for the company in FY 2026-27, fuelled by strong global demand. The worldwide market for these new APIs is currently valued at over Rs 5,000 crore, presenting substantial growth opportunities. 

Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.

Wanbury Share Price

185.00 21.90 (13.43%)
28-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.15
Dr. Reddys Lab 1224.30
Cipla 1328.25
Zydus Lifesciences 896.60
Lupin 2121.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×